CabozantinibMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3390668/fr/cabometyx-cabozantinib-carcinome-thyroidien-differencie
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
cabozantinib
thyroid neoplasms
carcinoma
Metastatic Differentiated Thyroid Gland Carcinoma
adult
Refractory Differentiated Thyroid Gland Carcinoma
antineoplastic agents
protein kinase inhibitors
evaluation of the transparency committee
cabozantinib

---
https://www.has-sante.fr/jcms/p_3297501/fr/opdivo-10-mg/ml-nivolumab-carcinome-a-cellules-renales-avance-en-association-cabozantinib
2021
France
evaluation of the transparency committee
carcinoma
Cell
Carcinoma
kidney, nos
Opdivo
"u" lymphocyte
cells
nivolumab
association
carcinoma, renal cell
Nivolumab
cabozantinib

---
https://www.has-sante.fr/jcms/p_3294121/fr/cabometyx-20-40-mg-cabozantinib-carcinome-a-cellules-renales-avance-en-association-au-nivolumab
2021
false
false
false
France
evaluation of the transparency committee
cells
carcinoma
nivolumab
Nivolumab
kidney, nos
"u" lymphocyte
traction
Cell
indication of
carcinoma, renal cell
association
indicators
cabozantinib
Carcinoma
indicators and reagents

---
https://www.has-sante.fr/jcms/p_3082106/fr/cabometyx
2019
false
false
false
France
evaluation of the transparency committee
cabozantinib
adult
treatment outcome
carcinoma, hepatocellular
cabozantinib
administration, oral
antineoplastic agents
protein kinase inhibitors
anilides
pyridines

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides

---
https://www.has-sante.fr/portail/jcms/c_2908453/fr/cabometyx
https://www.has-sante.fr/portail/jcms/c_2908453/fr/cabometyx-cabozantinib-inhibiteur-de-tyrosine-kinase
2019
false
false
false
false
France
French
treatment outcome
cabozantinib
carcinoma, renal cell
adult
cabozantinib
antineoplastic agents
protein kinase inhibitors
administration, oral
guidelines for drug use
evaluation of the transparency committee
anilides
pyridines

---
http://www.has-sante.fr/portail/jcms/c_2736733/fr/cabometyx
http://www.has-sante.fr/portail/jcms/c_2736733/fr/cabometyx-cabozantinib-inhibiteur-de-tyrosine-kinase
2017
false
false
false
France
French
treatment outcome
cabozantinib
anilides
pyridines
cabozantinib
carcinoma, renal cell
Advanced Malignant Neoplasm
Cabozantinib S-malate
receptor Protein-Tyrosine kinases
administration, oral
adult
protein kinase inhibitors
protein kinase inhibitors
survival analysis
evaluation of the transparency committee
clear cell renal cell carcinoma
guidelines for drug use
Tyrosine Kinase Inhibitors
cabozantinib
anilides
pyridines

---
https://www.ema.europa.eu/medicines/human/EPAR/Cabometyx
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
cabozantinib
anilides
pyridines
cabozantinib
drug approval
europe
drug interactions
pregnancy
breast feeding
carcinoma, renal cell
Advanced Malignant Neoplasm
Cabozantinib S-malate
receptor Protein-Tyrosine kinases
administration, oral
tablets
adult
protein kinase inhibitors
protein kinase inhibitors
risk assessment
product surveillance, postmarketing
survival analysis
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
cabozantinib
anilides
pyridines

---
https://ansm.sante.fr/tableau-atu-rtu/cabometyx-20-mg-40-mg-et-60-mg-comprime-pellicule
2016
false
false
false
France
French
cabozantinib
cabozantinib
guidelines for drug use
summary of product characteristics
package leaflet
cabozantinib
seborrhea sicca
dandruff
compression, nos
tablets
pill, nos
dandruff
anilides
pyridines
anilides
pyridines

---
http://www.has-sante.fr/portail/jcms/c_2007291/fr/cometriq
http://www.has-sante.fr/portail/jcms/c_2007291/fr/cometriq-cabozantinib-inhibiteur-de-tyrosine-kinase
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
anilides
anilides
pyridines
pyridines
receptor Protein-Tyrosine kinases
neoplasm metastasis
adult
thyroid cancer, medullary
treatment outcome
survival analysis
antineoplastic agents
antineoplastic agents
administration, oral
insurance, health, reimbursement
cabozantinib
late
Progression-Free survival
protein kinase inhibitors
protein kinase inhibitors
cabozantinib
cabozantinib
Tyrosine Kinase Inhibitors
disease-free survival
thyroid neoplasms

---
https://www.ema.europa.eu/medicines/human/EPAR/Cometriq
2014
false
United Kingdom
French
English
cabozantinib
cabozantinib
cabozantinib
drug approval
europe
summary of product characteristics
package leaflet
syndication feed
rare diseases
adult
thyroid cancer, medullary
orphan drug production
administration, oral
receptor Protein-Tyrosine kinases
treatment outcome
disease-free survival
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
contraception
thyroid cancer, medullary
drug evaluation, preclinical
antineoplastic agents
antineoplastic agents
thyroid neoplasms
thyroid neoplasms
anilides
anilides
pyridines
pyridines
Tyrosine Kinase Inhibitors

---